Good
Partially Aligned
Patient Risk:
Moderate
Summary
The AI claims about alcohol use and liver disease caution/contraindications are supported by the provided label excerpts. However, other included claims (e.g., beer/moderation guidance, drink limits, and standard drink definition) are not supported by the provided labeling text.
Category Scores
Accurate Statements
Statins (LIPITOR/atorvastatin) can be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease.
Section 5.2 Liver Dysfunction: “LIPITOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease.”
Active liver disease or unexplained persistent elevations in hepatic transaminases are contraindications to the use of LIPITOR.
Section 5.2 Liver Dysfunction: “Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of LIPITOR [see Contraindications (4.1)].” and Section 4.1 Active Liver Disease: “Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels.”
Statins like LIPITOR are associated with biochemical abnormalities of liver function (transaminase elevations).
Section 5.2 Liver Dysfunction: “Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function… Persistent elevations (>3 times the upper limit of normal [ULN]) in serum transaminases occurred…”
Liver function tests should be performed prior to and at 12 weeks following initiation and after any dose elevation, and periodically thereafter.
Section 17.2 Liver Enzymes and Section 5.2 Liver Dysfunction: “It is recommended that liver function tests be performed prior to and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter.”
Unsupported Statements
Drinking beer while taking Lipitor is generally considered safe in moderation.
The provided label excerpts do not state that beer is generally safe in moderation.
Moderate drinking for adults is defined as up to one drink per day for women.
The provided label excerpts do not define moderate drinking quantities or gender-based drink limits.
Moderate drinking for adults is defined as up to two drinks per day for men.
The provided label excerpts do not define moderate drinking quantities or gender-based drink limits.
A standard drink equals 12 ounces of regular beer at 5% alcohol content.
The provided label excerpts do not define a standard drink.
Health authorities advise against mixing statins and alcohol if the patient has liver disease or drinks heavily.
The provided label excerpts do not include 'health authorities' guidance or language framed as 'mixing' alcohol and statins.
Limiting alcohol intake helps avoid added stress on the liver.
The provided label excerpts do not support this rationale statement.
Excessive drinking combined with Lipitor can raise liver enzymes.
While the label cautions about substantial alcohol intake, the provided excerpts do not specifically claim that excessive drinking combined with Lipitor 'can raise liver enzymes.'
Excessive drinking combined with Lipitor can increase the risk of liver damage.
The provided label excerpts do not specifically state that alcohol + Lipitor increases risk of liver damage.
Patients taking atorvastatin who consume more than three drinks per day should talk to their doctor about possible alternatives or monitoring.
The provided label excerpts do not specify a threshold such as 'more than three drinks per day' or direct that specific advice.
Contradictions
Important Omissions
Recommended management actions when transaminases increase (e.g., monitoring until resolution; dose reduction/withdrawal if ALT or AST persist >3 times ULN).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several included statements give alcohol 'moderation' and numeric drink guidance not supported by the provided label excerpts; unsupported reassurance could affect patient decisions regarding alcohol intake. The label-supported caution/contraindication statements mitigate risk but do not cover the unsupported details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Numerous alcohol-quantity/beer/moderation/threshold guidance statements are not supported by the provided prescribing information excerpts.
Suggested Improvement
Limit the response to label-supported language: caution in substantial alcohol intake and history of liver disease; contraindications in active liver disease/unexplained persistent transaminase elevations; and label-supported liver function test timing and monitoring/dose adjustment approach if transaminases increase.